Abstract Using human papillomavirus (HPV) as a subunit vaccine and its manipulation of surface loops is current trending research. Since the atomic model of L1 protein conformations were deciphered, their manipulations of epitopes bring multivalent vaccines. Here, in the present study, we have manipulated antigenic loops of HPV 6b L1 capsid proteins in the amino acid regions 174 ~ 175 (L1:174EGFP) and 348 ~ 349 (L1:348EGFP) with whole enhanced green fluorescent protein(EGFP), expressed in the silkworm larva using Bombyx mori nucleopolyhedrovirus (BmNPV) bacmid technology. The expressed proteins were partially purified using sucrose density-gradient centrifugation and size-exclusion chromatography (SEC). The display of EGFP in virus-like particles (VLPs) was confirmed by immuno-fluorescence microscopy, Western blots and immune-transmission electron microscopy (immuno-TEM). There was higher expression of EGFP incorporated L1:174EGFP than L1:348EGFP. Hydrodynamic diameter of VLPs was corroborated by dynamic light scattering, confirming the size of expected range of around 160 nm and substantiating the incorporation of EGFP. From immuno-TEM, each L1:EGFP VLP formed small particles, suggesting that small particles of L1:EGFP fusion protein were aggregated. Our study illustrates that incorporation of whole protein can efficiently form chimeric VLPs, without hindering the conformation. HPV L1 protein accommodated a whole protein on its antigenic loop as a small particle, but an inserted whole protein was unstable.
Introduction
Human papillomaviruses are a group of double stranded DNA viruses that induce a range of illness in humans from low risk warts to cervical cancers. Human papillomavirus 6b L1 (HPV6b L1) virus infects mucosal epithelial tissues in genital areas resulting in benign lesions [1] . The structural protein of HPV consists of L1 and L2 capsid proteins; L1 having functions of virion formation and cell association where the latter is involved in membrane penetration, postentry trafficking, and genome encapsidation. The L1 is the primary capsid protein and is composed of approximately of 55 kDa, where 360 monomeric capsomere proteins assemble as 72 pentamers to form T = 7 icosahedral lattice. The fully assembled L1 virus particle has a size of around 60 nm in diameter. Conformation of L1 capsid protein assembly and its 5 surface antigenic loops BC, DE, EF, FG, and HI were solved using crystallographic studies [2, 3] .
Recombinant L1 capsid protein alone can be expressed in expression systems to form VLPs, which can elicit an immune response when used as subunit vaccines [4] [5] [6] [7] [8] . In addition, display of foreign protein in VLPs makes elicit immune response against both proteins [9] . Fusing or inserting epitopes or proteins onto the terminal regions of the capsid protein did not interfere with the conformations [10] [11] [12] [13] .
Previously, we have shown that the expression of full length HPV 6b L1 capsid protein could form efficiently VLPs, when expressed in silkworm-bacmid system [14] . In this work, we present the incorporation of whole EGFP into 2 antigenic loops of HPV 6b L1, expression using bacmid technology, and characterization of the VLP assembly.
Materials and Methods

Expression of HPV 6b L1 proteins
Two different surface loops incorporated with EGFP in HPV 6b L1 capsid protein was constructed as described previously [14] . In brief, each HPV 6b L1:EGFP fusion gene was obtained by a 2-step PCR. In addition, an EGFP gene was amplified by PCR and, a second PCR was performed using the amplified EGFP; the 2 amplified truncated L1 genes as a template and primers, respectively, to obtain L1:174EGFP fusion gene. The EGFP gene was inserted into EF loop between 174 and 175 amino acids in an L1-coding gene. Moreover, linker-region coding sequences (GGGGSGGGGS) were also added between L1 and EGFP genes. By this 2-step PCR, the EGFP gene was inserted into the HI loop between amino acids 348 and 349 to obtain an L1-coding gene (L1:348EGFP). Each amplified fusion gene was inserted at EcoRI-KpnI site in pFastBac1. The recombinant BmNPV CP -bacmid containing each HPV 6b L1:EGFP fusion gene was constructed according to the protocol described previously [14, 15] . The fifth instar Bombyx mori larvae were individually injected with 4 µg of chimeric HPV 6b L1:EGFP bacmids and reared in 25 o C incubator [15] . After 7 days, the fat body of each silkworm was collected and stored at -80 o C until use.
Purification of HPV 6B L1:EGFP chimeric VLPs
Extraction of expressed protein was achieved by sonicating the fat body using PBS (pH 7.4) containing 0.1% Triton-X100. The lysates were clarified using centrifugation at 30,000 g for 15 min. The clarified lysates were loaded on top of 25 ~ 60% sucrose density-gradient cushion and ultracentrifuged at 122,000 g for 3 h at 4 o C, and ultracentrifuged samples were collected in every 0.5 mL of fraction from the top of the tube to the bottom. The fractions containing target bands were detected by Western blot analysis. The fractions containing HPV 6b L1:EGFP chimeric VLPs were collected and loaded into HiLoad Superdex ™ 16/60 200 prep grad column, which was equilibrated with 3 column volumes of PBS (pH 7.4). The samples were eluted with PBS (pH 7.4) plus 0.5 M NaCl; 5 mL fractions were collected in fresh tubes and stored at 4 o C for further analysis.
Immunoblotting
Fractions from sucrose density-gradient and size-exclusion chromatography were subjected to immuno-analysis. A 30 µL of the fraction was mixed with 10 µL of sample buffer and 20 µL were loaded to SDS-PAGE gels, respectively. In order to perform Western blot analysis, the gel was transferred to PVDF membrane using Trans-blot ® semi-dry electrophoretic transfer cell (Bio-Rad, Hercules, CA, USA) at 15 V for 1 h. Next, the membrane transfer was blocked using 5% skim milk in Tris-buffered saline with 0.5% tween 20 (TBS-T) for 1 h. Washed 3 times with TBS-T and incubated with 1:5,000-diluted mouse anti-EGFP antibody (Clontech, Mountain View, CA, USA) for overnight at 4 o C. Anti-mouse secondary antibody conjugated with horseradish peroxidase (HRP) (1:10,000 diluted, GE Healthcare Japan, Tokyo, Japan) was used against the primary antibody, and incubated for 1 h at room temperature. Detection was carried out using Versa Doc Imager and analyzed using QuantityOne software (Bio-Rad).
Size analysis of chimeric VLPs
The partially purified HPV6b L1:EGFP chimeric variants were analyzed for hydrodynamic property and homogeneity using Dynamic Light Scattering (DLS) assay. One mL of PBS (pH 7.4) was mixed with L1:174EGFP and L1:348EGFP individually, and then diluted to 0.1 mg/mL. The samples were analyzed and calculated based on 10 successive measurements at 25 o C using Zetasizer nano ZS DLS analyzer fitted with 532 nm laser lamps (Malvern Instruments, UK).
Immuno-transmission electron microscopy (immuno-TEM)
The chimeric L1:EGFPP VLPs were immobilized on the carbon-coated grids. Dried for 15 min and blocked using 3% BSA for 30 min. Primary EGFP antibody (Clontech) diluted to 100-fold in blocking buffer (Tris-BSA) and adsorbed to grids for 1 h. After washing 5 times with TBS, the grids were soaked in 10 nm gold conjugated 1: 200 diluted mouse anti-IgG+IgM antibodies (BBI International, Ltd., Cardiff, UK) for 1 h. After washing, the grids were stained with 2% phosphotungstic acid and dried for 30 min. Then, VLPs were observed by TEM (JEM 2100, Japan) at 40,000 × magnifications.
Confocal laser scanning microscopy
Fresh fatbody cells containing HPV 6b L1 and L1:EGFP chimeric VLPs were washed 3 times in PBS, and fixed with 4% formaldehyde solution for 20 min at room temperature. Cells were permeabilized using 0.1% Triton-X100 in PBS for 20 min. Then, the cells were subjected to blocking with 3% BSA for 1 h and incubated with 1:100 dilution of EGFP primary antibody. Alexa fluor® 594 goat anti-mouse IgG (H+L) (Life Technol. Japan Co. Tokyo, Japan) was used as a secondary antibody. The cells were counterstained for nuclei using 4,6-diamidino-2-phenylindole (DAPI). Samples were observed using LSM 700 microscope (Zeiss, Jena, Germany) and images were analyzed by Zen2010 software.
Results and Discussion
Designing incorporation of EGFP in HPV 6b L1 VLPs
Chimeric HPV 6b L1 VLPs displaying EGFP as a model protein was designed in such a way that the incorporation was done in surface antigenic loops where the incorporated protein can be displayed. PCR was performed to insert the whole EGFP protein into the HPV 6b L1 EF and HI epitopes by specific primers (Fig. 1A) . Previously, it was demonstrated that bovine papillomavirus (BPV) L1 protein inserted human mucin 1 (MUC1) peptide into its HI loop can assemble into VLP, but BPV L1 protein inserted the same peptide into BC and DE loops cannot be assembled [16] . In addition, EF loop localizes the outermost L1 pentamer [3] . Therefore, EF and HI loops were selected to insert EGFP in this study. Moreover, it was previously reported that use of flexible linkers allows the incorporated whole protein to flexibly move to take conformation [17] . Therefore, we added a double GGGGS linker sequence that was placed in the N-terminal and C-terminal of the EGFP protein. Since EGFP has green fluorescence when it is in the correct conformation, whether expressed L1:EGFP chimeric proteins have correct conformation or not can be easily confirmed by its green fluorescence. The chimeric constructs were ligated in the EcoRI and KpnI regions of pFastbacI plasmid and transformed to BmNPV CP -bacmid to express in silkworm larvae (Fig. 1B) .
Expression and purification of HPV 6b L1:EGFP chimeric VLPs
Expression of each HPV 6b L1:EGFP chimeric VLPs was confirmed in silkworm larvae by observing under UV Fig. 1 . Schematic representation of chimeric HPV 6B L1:EGFP construction. Using PCR technology whole protein EGFP was constructed (A), the constructed HPV 6b L1:EGFP chimeric VLPs were ligated with pFastbac1 EcoRI and KpnI restriction site and transformed to E. coli BmDH10 Bac CP -and the bacmid was injected to silkworm larvae for expression.
transilluminator (data not shown). The fatbody samples were sonicated and the clarified lysates were applied to 25 60% sucrose density-gradient ultracentrifugation and the fraction (Fractions 3 ~ 6 in all 10 fractions) containing 83 kDa of HPV 6b L1:174EGFP and L1:348EGFP chimeric VLPs along with degraded proteins were confirmed by Western blot (Fig. 2) . The expression levels of the 2 constructs varied, and L1:174EGFP (150 µg/larval hemolymph mL) was comparatively higher than L1:348EGFP (62 µg/larval hemolymph mL). Fractions containing each L1:EGFP chimeric VLP were collected and further purified by size exclusion chromatography using Hiload superdex ™ 16/60 200 prep grade column. L1:174EGFP and L1:348EGFP chimeric VLPs were eluted at 35 ~ 55 mL and 40 ~ 50 mL, respectively, on this SEC column. Partially purified fractions were recovered.
Confirmation of size and structural integrity
To determine the conformation of HPV 6b L1:EGFPP chimeric VLPs, dynamic light scattering was carried out [18] . The sizes of chimeric L1:174EGFP (Fig. 3A) and L1:348EGFP (Fig. 3B) were 156 and 155 nm, respectively (at pH 7.4, 25 o C), which are bigger than HPV 6b L1 VLP alone (~ 60 nm). Size of HPV L1 VLP is normally 55 nm in diameter. In this study, each purified L1:EGFP chimeric VLP has approximately 155 nm in diameter. From immuno-TEM images, these purified chimeric VLPs formed small particles and these particles were aggregated. In addition, gold nanoparticles were observed on the small particles and aggregates composed of each chimeric VLP, indicating that EGFP were displayed on the surface of these particles.
Localization of HPV 6b L1:EGFP chimeric VLPs in fat body cells of silkworm larvae
To prove that the HPV 6b L1 chimeric VLPs with EGFP incorporation expressed in silkworm larvae have native conformation, the fat body was immuno-labeled with EGFP antibodies [19] . As shown in Fig. 4 , the EGFP fluorescence at 488 nm was observed in the cytoplasm of cells where L1:174EGFP or L1:348EGFP was expressed. With immuno-labeling with Alexa Fluor® 594, we can confirm that its red fluorescence coincided with the EGFP fluorescence, indicating that each expressed L1:EGFP chimeric VLPs had EGFP fluorescence. This result is contradictory to a previous report, which mentioned that these L1:EGFP chimeric VLPs did not show EGFP fluorescence [14] . In a previous study, the fat body homogenate was applied to HiTrap heparin affinity column chromatography and Mono S 5/50GL column chromatography in series. However, after purification, the fluorescence of each purified L1:EGFP chimeric VLP was not detected (Data not shown). In this study, the purification was modified as follows: the VLPs were separated from the fat body homogenate by sucrose density-gradient ultracentrifugation and were applied to HiLoad Superdex 16/60 200 prep grad column. However, any fluorescence of each purified L1:EGFP chimeric VLPs was not detected. This indicates that purification of HPV 6b L1 VLPs using columns affects the structural integrity or immune response. In addition, Kim et al. reported that choice of resin-bound ligand affects the structural and immunogenity of column-purified human papillomavirus type 16 VLPs [20] . On the other hand, fat body cells and silkworm larvae where each L1:EGFP chimeric VLP were expressed showed EGFP fluorescence. This suggests that L1:174EGFP and L1:348EGFP chimeric VLPs had EGFP fluorescence in vivo, but after extraction and purification processes, its EGFP fluorescence disappeared because of its instability or conformational change in vitro.
Conclusion
Display of foreign proteins on the surface of VLPs has many advantages, for example use as multiple antigenic vaccines or traffic studies of signaling. Our study suggests that incorporating whole protein in VLPs can be helpful in further incorporations like other L1 capsid protein/epitopes or mutualistic/opportunistic diseases associated with papillomavirus. This technology can provide the formation of chimeric VLPs using epitope loop without compromising the conformation of VLPs. 
